Please Click on Publication Title to Download. Publications are sorted by catagory: General Interest, 5-FU, 5-FU Abstracts or Busulfan.
General Interest
Mathijssen RHJ, de Jong FA, Loos WJ, van der Bol JM, Verweij J, Sparreboom A. Flat-fixed dosing versus body surface area-based dosing of anticancer drugs in adults: Does it make a difference? Oncologist. 2007;12:913-923. doi:10.1634/theoncologist.12-8-913.
de Jonge ME, Huitema ADR, Schellens JHM, Rodenhuis S, Beijnen JH. Individualised cancer chemotherapy: Strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review. Clin Pharmacokinet. 2005;44(2):147-173.
Undevia SD, Gomez-Abuin G, Ratain MJ. Pharmacokinetic variability of anticancer agents. Nat Rev Cancer. 2005;5(6):447-458.
Chabner BA, Roberts TG Jr. Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer. 2005;5(1):65-72.
Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21(24):4524-4531.
Rousseau A, Marquet P. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam Clin Pharmacol. 2002;16(4):253-262.
Krynetski EY, Evans WE. Pharmacogenetics of cancer therapy: getting personal. Am J Hum Genet. 1998;63(1):11-16.
Galpin AJ, Evans WE. Therapeutic drug monitoring in cancer management. Clin Chem. 1993;39(11, Pt 2):2419-2430.
5-Fluorouracil (5-FU)
Beumer, J.H., Boisdron-Celle, M., et.al. Multicenter Evaluation of a Novel Nanoparticle Immunoassay for 5-Fluorouracil on the Olympus AU400 Analyzer. Therapeutic Drug Monitoring, 2009; 31(96), 688-94.
Saif, A., Choma, A, Salamone, S. & Chu, E. Pharmacokinetically guided dose adjustment of 5-Fluorouracil: A rational approach to improving therapeutic outcomes. Journal of the National Cancer Institute, 2009;101: 1 - 10.
Di Paolo A, Lencioni M, Amatori F, et al. 5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer. Clin Cancer Res. 2008;14(9):2749-2755.
Walko CM, McCloud HL. Will we ever be ready for blood level-guided therapy? [editorial]. J Clin Oncol. 2008;26(13):2078-2079.
Gamelin E, Delva R, Jacob J, et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: Results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(13):2099-2105.
Bertino J, Fleisher M, Beumer J, et al; ASCO Participants. 5-fluorouracil drug management pharmacokinetics and pharmacogenomics workshop; Orlando, Florida, January 2007 [meeting highlights]. Clin Colorectal Cancer. 2007;6(6):407-422.
5-fluorouracil (5-FU) Abstracts
Abstract 429: Capitain et al. Influence of Pharmacogenetic Polymorphisms on 5-fluorouracil and Irinotecan Efficacy and Tolerance in Patients Treated for Advanced Colorectal Cancer. 2008 ASCO Gastrointestinal Cancer Symposium, January 2008.
Salamone SJ, Courtney JB, Li Y, Stocker D, Colvin OM. A library of novel monoclonal antibodies for determining levels of 4-hydroxy cyclophosphamide in biological fluids [AACR Proceedings, December 2008, abstract 3107]. Proc Amer Assoc Cancer Res. 2006;47.
Abstract 431: Gamelin et al. 5-FU Dose Monitoring and Prevention of Oxaliplatin-Induced Neurotoxicity in FOLFOX 4 Regimen: Results of a Phase II Study. 2008 ASCO Gastrointestinal Cancer Symposium, January 2008.
Abstract 421: Beumer et al. A rapid nano particle immunoassay to quantitate 5-fluorouracil (5-FU) in plasma. 2008 ASCO Gastrointestinal Cancer Symposium, January 2008
Abstract HOPA,08: Salamone et al. A multi-center evaluation of a rapid immunoassay to quantitate 5-fluorouracil (5-FU) in plasma. HOPA/ISOPP 2008 Conference June, 2008.
Salamone SJ, Courtney JB, Stocker D, Harney RL. Novel monoclonal antibodies for measuring 5-fluorouracil concentrations in biological fluids [ASCO Annual Meeting Proceedings Part I, Vol.24, abstract 2055]. J Clin Oncol. 2006;June 20 (suppl):18S.
BusulfanSalamone SJ, Courtney J, Harney R, He S, Lundell G. A rapid immunoassay to determine concentrations of busulfan in plasma [ASCO Annual Meeting Proceedings Part I, Vol. 25, abstract 7111]. J Clin Oncol. 2007;June 20 (suppl):18S.
Oechtering D, Schiltmeyer B, Hempel G, et al. Toxicity and pharmacokinetics of i.v. busulfan in children before stem cell transplantation. Anti-Cancer Drugs. 2005;16(3):337-344.
Slattery JT. Intravenous versus oral busulfan - perhaps not as different as suggested [letter]. Biol Blood Marrow Transplantation. 2003;9(4):282-284.